Martin R Turner

List of Publications by Year in Descending Order

222 papers	13,114 citations	58 h-index	110 g-index
255 ext. papers	16,333 ext. citations	6.2 avg, IF	6.39 L-index

#	Paper	IF	Citations
222	Modeling seeding and neuroanatomic spread of pathology in amyotrophic lateral sclerosis.. *NeuroImage*, **2022**, 251, 118968	7.9	0
221	Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain.. *Brain Communications*, **2022**, 4, fcac029	4.5	2
220	Clinical trials in pediatric ALS: a TRICALS feasibility study.. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2022**, 1-8	3.6	1
219	The Digital Brain Bank, an open access platform for post-mortem datasets.. *ELife*, **2022**, 11,	8.9	1
218	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. *Expert Review of Proteomics*, **2021**, 1-18	4.2	1
217	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. *Brain*, **2021**,	11.2	4
216	Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS. *Frontiers in Neuroscience*, **2021**, 15, 642324	5.1	1
215	Isolated homozygous R217X mutation causes knock-out of functional C-terminal optineurin domains and associated oligodendrogliopathy-dominant ALS-TDP. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 1022-1024	5.5	0
214	Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers. *Nature Reviews Neurology*, **2021**, 17, 333-348	15	15
213	Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP. *Brain Pathology*, **2021**, 31, e12923	6	6
212	Improving clinical trial outcomes in amyotrophic lateral sclerosis. *Nature Reviews Neurology*, **2021**, 17, 104-118	15	46
211	Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. *Brain Communications*, **2021**, 3, fcab168	4.5	12
210	To Zoom or Not to Zoom: The Should I Travel Index Revisited during the Coronavirus Disease Pandemic. *Annals of Neurology*, **2021**, 89, 1057-1058	9.4	0
209	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2021**, 22, 276-286	3.6	5
208	Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 510-518	5.5	20
207	REM sleep physiology and selective neuronal vulnerability in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 789-790	5.5	1
206	Evolution of white matter damage in amyotrophic lateral sclerosis. *Annals of Clinical and Translational Neurology*, **2020**, 7, 722-732	5.3	6

205	The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 563-573	3.6	2
204	Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. *Human Molecular Genetics*, **2020**, 29, 2200-2217	5.6	14
203	A multi-center study of neurofilament assay reliability and inter-laboratory variability. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 452-458	3.6	8
202	Primary lateral sclerosis: diagnosis and management. *Practical Neurology*, **2020**, 20, 262-269	2.4	8
201	Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis. *Brain Communications*, **2020**, 2, fcaa053	4.5	14
200	Reply to: Early white matter changes on diffusion tensor imaging in amyotrophic lateral sclerosis. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1266-1267	5.3	
199	Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry,the*, **2020**, 7, 875-882	23.3	615
198	Regional callosal integrity and bilaterality of limb weakness in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 396-402	3.6	8
197	Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 227-234	5.5	14
196	Primary lateral sclerosis: consensus diagnostic criteria. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 373-377	5.5	59
195	The clinical spectrum of primary lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 3-10	3.6	5
194	Neurophysiological features of primary lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 11-17	3.6	4
193	Neuroimaging in primary lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2020**, 21, 18-27	3.6	8
192	An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. *Neurobiology of Disease*, **2020**, 144, 105050	7.5	7
191	Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. *NeuroImage*, **2020**, 222, 117216	7.9	14
190	Characterising neuropsychiatric disorders in patients with COVID-19 - AuthorsQreply. *Lancet Psychiatry,the*, **2020**, 7, 934-935	23.3	7
189	Quantitative patterns of motor cortex proteinopathy across ALS genotypes. *Acta Neuropathologica Communications*, **2020**, 8, 98	7.3	12
188	CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1296-1306	5.3	15

187	Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. *Neurology*, **2020**, 95, 595-596	6.5	5
186	CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis. *Clinical Proteomics*, **2020**, 17, 31	5	13
185	A proposal for new diagnostic criteria for ALS. *Clinical Neurophysiology*, **2020**, 131, 1975-1978	4.3	91
184	Clinic letters revisited. *Practical Neurology*, **2019**, 19, 457	2.4	
183	Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. *Brain*, **2019**, 142, 586-605	11.2	44
182	Cerebellar tract alterations in PLS and ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 281-284	3.6	18
181	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurology*, **2019**, 76, 1035-1048	17.2	237
180	CSF chitinase proteins in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 1215-1220	5.5	32
179	Therapeutic non-invasive brain stimulation in amyotrophic lateral sclerosis: rationale, methods and experience. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 1131-1138	5.5	3
178	Defining pre-symptomatic amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2019**, 20, 303-309	3.6	27
177	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. *Neurology*, **2019**, 92, e1610-e1623	6.5	74
176	Relative preservation of triceps over biceps strength in upper limb-onset ALS: the ☺plit elbowQ *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 730-733	5.5	19
175	Tracheostomy in motor neurone disease. *Practical Neurology*, **2019**, 19, 467-475	2.4	7
174	Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study. *JMIR MHealth and UHealth*, **2019**, 7, e13433	5.5	13
173	Frequency and signature of somatic variants in 1461 human brain exomes. *Genetics in Medicine*, **2019**, 21, 904-912	8.1	14
172	Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 570-575	5.5	7
171	Imaging Cerebral Activity in Amyotrophic Lateral Sclerosis. *Frontiers in Neurology*, **2018**, 9, 1148	4.1	30
170	Towards a TDP-43-Based Biomarker for ALS and FTLD. *Molecular Neurobiology*, **2018**, 55, 7789-7801	6.2	58

169	Increased cerebral functional connectivity in ALS: A resting-state magnetoencephalography study. *Neurology*, **2018**, 90, e1418-e1424	6.5	15
168	Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2018**, 129, 1479-1489	4.3	21
167	The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis. *NeuroImage: Clinical*, **2018**, 17, 953-961	5.3	64
166	Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. *Annals of Neurology*, **2018**, 83, 258-268	9.4	69
165	Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 813-816	5.5	11
164	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. *Alzheimer's Research and Therapy*, **2018**, 10, 30	9	29
163	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. *Lancet Neurology, The*, **2018**, 17, 423-433	24.1	189
162	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron*, **2018**, 97, 1268-1283.e6	13.9	296
161	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. *World Journal of Biological Psychiatry*, **2018**, 19, 244-328	3.8	148
160	Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 1250-1258	5.5	25
159	Amyotrophic lateral sclerosis: the complex path to precision medicine. *Journal of Neurology*, **2018**, 265, 2454-2462	5.5	21
158	Dissecting the pathobiology of altered MRI signal in amyotrophic lateral sclerosis: A post mortem whole brain sampling strategy for the integration of ultra-high-field MRI and quantitative neuropathology. *BMC Neuroscience*, **2018**, 19, 11	3.2	26
157	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. *Neurology*, **2018**, 90, e22-e30	6.5	106
156	Kinnier Wilson's puzzling features of amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 657-666	5.5	3
155	UFLC-Derived CSF Extracellular Vesicle Origin and Proteome. *Proteomics*, **2018**, 18, e1800257	4.8	18
154	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. *Neurobiology of Aging*, **2018**, 71, 266.e1-266.e10	5.6	44
153	A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 243-248	3.6	10
152	Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. *Acta Neuropathologica Communications*, **2017**, 5, 13	7.3	55

151	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. *Science Translational Medicine*, **2017**, 9,	17.5	74
150	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. *Brain*, **2017**, 140, 887-897	11.2	94
149	Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. *Genome Research*, **2017**, 27, 165-173	9.7	36
148	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 153-174	3.6	371
147	The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 569-575	3.6	26
146	Defective cholesterol metabolism in amyotrophic lateral sclerosis. *Journal of Lipid Research*, **2017**, 58, 267-278	6.3	73
145	Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. *Neurotherapeutics*, **2017**, 14, 11-23	6.4	45
144	A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2017**, 18, 1-9	3.6	14
143	Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis. *Human Brain Mapping*, **2017**, 38, 237-254	5.9	40
142	Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis. *Academic Radiology*, **2017**, 24, 1187-1194	4.3	18
141	Nutritional pathway for people with motor neurone disease. *British Journal of Community Nursing*, **2016**, 21, 360-3	0.6	1
140	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. *Nature Genetics*, **2016**, 48, 1037-42	36.3	149
139	Romberg test no longer stands up. *Practical Neurology*, **2016**, 16, 316	2.4	2
138	Psychiatric disorders prior to amyotrophic lateral sclerosis. *Annals of Neurology*, **2016**, 80, 935-938	9.4	29
137	Motor neurone disease: not just motor and no longer one disease. *British Journal of Neuroscience Nursing*, **2016**, 12, 214-215	0.1	
136	Assessment of the upper motor neuron in amyotrophic lateral sclerosis. *Clinical Neurophysiology*, **2016**, 127, 2643-60	4.3	67
135	Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 244-6	5.5	24
134	The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 414-25	3.6	46

133	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1000-4	5.5	50
132	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 570-9	5.5	110
131	Preface to 'Neuromythology' *Practical Neurology*, **2016**, 16, 315	2.4	
130	Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 580-8	5.5	62
129	Motor neuron disease: biomarker development for an expanding cerebral syndrome. *Clinical Medicine*, **2016**, 16, s60-s65	1.9	4
128	Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 600-604	3.6	6
127	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2016**, 17, 404-13	3.6	65
126	Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. *Nature Reviews Neurology*, **2016**, 12, 346-57	15	190
125	C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. *Stem Cells*, **2016**, 34, 2063-78	5.8	133
124	Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 17, 101-11	3.6	43
123	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2015**, 14, 786-788	24.1	31
122	The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 16, 456-63	3.6	32
121	The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 667-73	5.5	74
120	Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 16, 442-7	3.6	2
119	The Role of Neuroimaging in Amyotrophic Lateral Sclerosis **2015**, 787-797		
118	Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. *Neurology*, **2015**, 84, 2247-57	6.5	293
117	Mind the gap: the mismatch between clinical and imaging metrics in ALS. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 16, 524-9	3.6	47
116	Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. *Muscle and Nerve*, **2015**, 51, 14-8	3.4	41

115	Progressive hemiparesis in a 75-year-old man. *Practical Neurology*, **2015**, 15, 63-71	2.4	5
114	Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 45-9	5.5	58
113	Identification of distinct circulating exosomes in Parkinson disease. *Annals of Clinical and Translational Neurology*, **2015**, 2, 353-61	5.3	93
112	CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. *Annals of Clinical and Translational Neurology*, **2015**, 2, 748-55	5.3	99
111	What does imaging reveal about the pathology of amyotrophic lateral sclerosis?. *Current Neurology and Neuroscience Reports*, **2015**, 15, 45	6.6	48
110	Lou Gehrig and the ALS split hand. *Neurology*, **2015**, 85, 1995	6.5	4
109	Does dysfunction of the mirror neuron system contribute to symptoms in amyotrophic lateral sclerosis?. *Clinical Neurophysiology*, **2015**, 126, 1288-94	4.3	12
108	Seasonal variation in Guillain-Barr syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1196-201	5.5	51
107	Advances in motor neurone disease. *Journal of the Royal Society of Medicine*, **2014**, 107, 14-21	2.3	75
106	Progressive hemiparesis (Mills syndrome) with aphasia in amyotrophic lateral sclerosis. *Neurology*, **2014**, 82, 457-8	6.5	11
105	Tools and talk: an evolutionary perspective on the functional deficits associated with amyotrophic lateral sclerosis. *Muscle and Nerve*, **2014**, 49, 469-77	3.4	31
104	Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. *Neuron*, **2014**, 84, 324-31	13.9	229
103	Quantifying disease progression in amyotrophic lateral sclerosis. *Annals of Neurology*, **2014**, 76, 643-57	9.4	102
102	Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) in the older adult. *Practical Neurology*, **2014**, 14, 432-6	2.4	14
101	An elusive cause for a progressive neuropathy. *Practical Neurology*, **2014**, 14, 45-9	2.4	
100	Magnetoencephalography. *Practical Neurology*, **2014**, 14, 336-43	2.4	37
99	Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2014**, 15, 279-84	3.6	65
98	Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2014**, 15, 285-91	3.6	21

97	T2-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 785-93	7.3	28
96	Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. *Brain*, **2014**, 137, 2546-55	11.2	126
95	A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. *Neurology*, **2014**, 83, 1492-9	6.5	60
94	CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. *Acta Neuropathologica Communications*, **2014**, 2, 66	7.3	18
93	Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?. *Alzheimer's Research and Therapy*, **2014**, 6, 51	9	21
92	Swallowing and oropharyngeal dysphagia. *Clinical Medicine*, **2014**, 14, 456	1.9	1
91	Voxel-based MRI intensitometry reveals extent of cerebral white matter pathology in amyotrophic lateral sclerosis. *PLoS ONE*, **2014**, 9, e104894	3.7	16
90	Unmasking of incipient amyotrophic lateral sclerosis by botulinum toxin therapy. *Journal of Neurology*, **2013**, 260, 1166-7	5.5	7
89	Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level?. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 487-93	3.6	21
88	Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14 Suppl 1, 19-32	3.6	114
87	Management of sialorrhoea in motor neuron disease: a survey of current UK practice. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 521-7	3.6	22
86	Controversies and priorities in amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2013**, 12, 310-22	24.1	377
85	Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis. *Academic Radiology*, **2013**, 20, 1099-106	4.3	61
84	Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary trade-off?. *Clinical Genetics*, **2013**, 83, 588-90	4	12
83	Inflammation and neurovascular changes in amyotrophic lateral sclerosis. *Molecular and Cellular Neurosciences*, **2013**, 53, 34-41	4.8	135
82	Mimics and chameleons in motor neurone disease. *Practical Neurology*, **2013**, 13, 153-64	2.4	63
81	Progressive dysphagia without dysarthria. *Practical Neurology*, **2013**, 13, 197	2.4	2
80	Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. *Neurology*, **2013**, 80, 610-5	6.5	44

79	Myelin imaging in amyotrophic and primary lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 562-73	3.6	48
78	Peer recommendations on how to improve clinical research, and Conference wrap-up. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14 Suppl 1, 67-73	3.6	1
77	Promoting clinical and patient-oriented research to identify the pathogenesis of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14 Suppl 1, 1-4	3.6	0
76	Amyotrophic lateral sclerosis and cancer: a register-based study in Sweden. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 362-8	3.6	29
75	Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. *Neurology*, **2013**, 81, 1222-5	6.5	104
74	The wisdom of neurologists. *Practical Neurology*, **2013**, 13, 350	2.4	1
73	Unilateral leukonychia and hair depigmentation in multifocal motor neuropathy. *Neurology*, **2013**, 81, 1800-1	6.5	2
72	Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis. *PLoS ONE*, **2013**, 8, e85190	3.7	44
71	An eye-tracking version of the trail-making test. *PLoS ONE*, **2013**, 8, e84061	3.7	14
70	Motor neurone disease is a clinical diagnosis. *Practical Neurology*, **2012**, 12, 396-7	2.4	6
69	Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2012**, 13, 245-50		104
68	Neuroimaging in amyotrophic lateral sclerosis. *Biomarkers in Medicine*, **2012**, 6, 319-37	2.3	112
67	Magnetic resonance imaging of pathological processes in rodent models of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2012**, 13, 288-301		7
66	A proposed staging system for amyotrophic lateral sclerosis. *Brain*, **2012**, 135, 847-52	11.2	203
65	Teaching video neuroimages: acute Adie syndrome. *Neurology*, **2012**, 79, e97	6.5	3
64	Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 395-8	5.5	48
63	Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. *Archives of Neurology*, **2012**, 69, 1493-9		55
62	Teaching NeuroImages: somatic muscle fasciculations detected by electrocardiography. *Neurology*, **2012**, 78, e19	6.5	2

61	Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 382	5.5	1
60	Young-onset amyotrophic lateral sclerosis: historical and other observations. *Brain*, **2012**, 135, 2883-91	11.2	47
59	Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. *Nature Reviews Neurology*, **2011**, 7, 631-8	15	74
58	Diffusion imaging of whole, post-mortem human brains on a clinical MRI scanner. *NeuroImage*, **2011**, 57, 167-181	7.9	193
57	Amyotrophic lateral sclerosis. *Lancet, The*, **2011**, 377, 942-55	40	1665
56	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2011**, 10, 400-3	24.1	129
55	Neurogastroentrology: an A to Z. *Practical Neurology*, **2011**, 11, 220-30	2.4	
54	Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. *Brain*, **2011**, 134, 3470-9	11.2	195
53	Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 635-7	5.5	41
52	Oculomotor dysfunction in amyotrophic lateral sclerosis: a comprehensive review. *Archives of Neurology*, **2011**, 68, 857-61		95
51	Epilepsy and the subsequent risk of cerebral tumour: record linkage retrospective cohort study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1041-5	5.5	8
50	Catastrophic hyperkalaemia following administration of suxamethonium chloride to a patient with undiagnosed amyotrophic lateral sclerosis. *Clinical Medicine*, **2011**, 11, 292-3	1.9	9
49	Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 215-21	5.5	97
48	Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 255-7		1
47	Advances in the application of MRI to amyotrophic lateral sclerosis. *Expert Opinion on Medical Diagnostics*, **2010**, 4, 483-496		51
46	Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis. *Brain*, **2010**, 133, 3470-9	11.2	15
45	Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. *Journal of the Neurological Sciences*, **2010**, 288, 45-8	3.2	43
44	The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*, **2010**, 294, 81-5	3.2	70

43	The sex ratio in amyotrophic lateral sclerosis: A population based study. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 439-42		105
42	Some difficult decisions in ALS/MND. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 339-43		58
41	Public awareness of motor neuron disease. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 490-1		6
40	Pattern of spread and prognosis in lower limb-onset ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 369-73		47
39	The internet for self-diagnosis and prognostication in ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 565-7		11
38	The association between ALS and population density: A population based study. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2010**, 11, 435-8		15
37	Trends in death certification for multiple sclerosis, motor neuron disease, Parkinson's disease and epilepsy in English populations 1979-2006. *Journal of Neurology*, **2010**, 257, 706-15	5.5	32
36	Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. *Human Molecular Genetics*, **2009**, 18, 472-81	5.6	421
35	Geographical clustering of amyotrophic lateral sclerosis in South-East England: a population study. *Neuroepidemiology*, **2009**, 32, 81-8	5.4	34
34	Diffusion tensor imaging in sporadic and familial (D90A SOD1) forms of amyotrophic lateral sclerosis. *Archives of Neurology*, **2009**, 66, 109-15		35
33	Child neurology: a growing skull fracture. *Neurology*, **2009**, 72, e38	6.5	2
32	Biomarkers in amyotrophic lateral sclerosis. *Lancet Neurology, The*, **2009**, 8, 94-109	24.1	340
31	The borderland of neuromyelitis optica. *Practical Neurology*, **2009**, 9, 335-40	2.4	4
30	Functional vitamin B12 deficiency. *Practical Neurology*, **2009**, 9, 37-41	2.4	26
29	When to consider thyroid dysfunction in the neurology clinic. *Practical Neurology*, **2009**, 9, 145-56	2.4	22
28	Teaching video NeuroImage: the "Fonzarelli" sign: focal thumb dystonia as an early manifestation of Parkinson disease. *Neurology*, **2008**, 71, e11	6.5	
27	What is the place of thrombolysis in acute stroke? A review of the literature and a current perspective. *Clinical Medicine*, **2008**, 8, 253-8	1.9	6
26	Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: an (11C)-flumazenil PET study. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2008**, 9, 43-9		41

25	Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET. *Journal of Neurology*, **2007**, 254, 1033-6	5.5	33
24	A case of celiac disease mimicking amyotrophic lateral sclerosis. *Nature Clinical Practice Neurology*, **2007**, 3, 581-4		18
23	Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2007**, 8, 343-7		39
22	Large-scale pathways-based association study in amyotrophic lateral sclerosis. *Brain*, **2007**, 130, 2292-301	11.2	29
21	Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. *Journal of Neurology*, **2006**, 253, 1642-3	5.5	147
20	Comparison of two percutaneous radiological gastrostomy tubes in the nutritional management of ALS patients. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2005**, 6, 177-81		19
19	Reversible diffusion MRI abnormalities and transient mutism after liver transplantation. *Neurology*, **2005**, 64, 177; author reply 177	6.5	7
18	Delayed recovery of ulnar neuropathy due to elbow warming. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1268	5.5	
17	A novel central motor conduction abnormality in D90A-homozygous patients with amyotrophic lateral sclerosis. *Muscle and Nerve*, **2004**, 29, 790-4	3.4	8
16	Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. *Neurobiology of Disease*, **2004**, 15, 601-9	7.5	547
15	Chapter 21 Disease-Modifying Therapies in Motor Neuron Disorders: The Present Position and Potential Future Developments. *Blue Books of Practical Neurology*, **2003**, 28, 497-544		1
14	Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. *Annals of Neurology*, **2003**, 54, 130-4	9.4	32
13	Riluzole and Motor Neurone Disease. *Practical Neurology*, **2003**, 3, 160-169	2.4	3
12	Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphoma. *Journal of the Peripheral Nervous System*, **2003**, 8, 100-7	4.7	9
11	Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2002**, 3, 15-21		68
10	Starting a research post: some considerations for ward-based doctors. *British Journal of Hospital Medicine*, **2001**, 62, 627-30		2
9	Clinical trials in ALS: an overview. *Seminars in Neurology*, **2001**, 21, 167-75	3.2	32
8	Positron emission tomography (PET) its potential to provide surrogate markers in ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2000**, 1, s17-s22		13

7	Positron emission tomography (PET)--its potential to provide surrogate markers in ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases*, **2000**, 1 Suppl 2, S17-22		11
6	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. *SSRN Electronic Journal*,	1	2
5	Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair		1
4	Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T		2
3	Tensor Image Registration Library: Automated Non-Linear Registration of Sparsely Sampled Histological Specimens to Post-Mortem MRI of the Whole Human Brain		6
2	The Digital Brain Bank, an open access platform for post-mortem datasets		2
1	Creatine kinase and prognosis in amyotrophic lateral sclerosis: a literature review and multi-centre cohort analysis. *Journal of Neurology*,	5.5	0